ACT 903
Alternative Names: ACT-903Latest Information Update: 05 Jun 2023
Price :
$50 *
At a glance
- Originator Alpha Cancer Technologies; PolyTherics
- Class Antineoplastics; Drug conjugates; Maytansinoids; Recombinant proteins
- Mechanism of Action Apoptosis stimulants; Mitosis inhibitors; Tubulin inhibitors; Tubulin polymerisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Haematological malignancies; Solid tumours
Most Recent Events
- 05 Jun 2023 Pharmacodynamics and adverse events data from a preclinical trial in solid tumours released by Alpha Center Technologies
- 08 Jul 2022 Pharmacodynamics and pharmacokinetics data from preclinical studies in Solid tumours presented at the 58th Annual Meeting of the American Society of Clinical Oncology (ASCO-2022)
- 21 Sep 2021 Alpha Cancer Technologies announces intention to submit IND for Solid tumours and Haematological malignancies in 2024